These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 100708)

  • 21. Treatment for LSDs: no longer just enzyme replacement therapy for Gaucher disease. Foreword.
    Cohen IJ; Baris H; Mistry PK
    Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():58. PubMed ID: 24380122
    [No Abstract]   [Full Text] [Related]  

  • 22. Potential applications of liposomes to therapy.
    Ryman BE; Jewkes RF; Jeyasingh K; Osborne MP; Patel HM; Richardson VJ; Tattersall MH; Tyrrell DA
    Ann N Y Acad Sci; 1978; 308():281-307. PubMed ID: 358897
    [No Abstract]   [Full Text] [Related]  

  • 23. Diphenylhydantoin treatment of glycogen storage diseases.
    Jubiz W; Rallison ML
    Arch Intern Med; 1974 Sep; 134(3):418-21. PubMed ID: 4368592
    [No Abstract]   [Full Text] [Related]  

  • 24. [Macula findings in thesaurismoses].
    François J
    Ber Zusammenkunft Dtsch Ophthalmol Ges; 1975; (73):223-65. PubMed ID: 54161
    [No Abstract]   [Full Text] [Related]  

  • 25. Enzyme replacement using liposome carriers in feline Gm1 gangliosidosis fibroblasts.
    Reynolds GC; Baker HJ; Reynolds RH
    Nature; 1978 Oct; 275(5682):754-5. PubMed ID: 100709
    [No Abstract]   [Full Text] [Related]  

  • 26. Developing novel chemical entities for the treatment of lysosomal storage disorders: an academic perspective.
    Shayman JA
    Am J Physiol Renal Physiol; 2015 Dec; 309(12):F996-9. PubMed ID: 26447223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrathecal Baclofen Pump Implantation for Type 2 Gaucher Disease.
    Hori YS; Fukuhara T; Aoi M; Ochi M; Furujo M
    Pediatr Neurosurg; 2017; 52(5):331-335. PubMed ID: 28848108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Lysosomal storage diseases: possibilities of the ultrastructural diagnosis (author's transl)].
    Spycher MA; Gitzelmann R; Wiesmann UN
    Verh Dtsch Ges Pathol; 1976; ():110-9. PubMed ID: 828814
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacologic chaperoning as a strategy to treat Gaucher disease.
    Yu Z; Sawkar AR; Kelly JW
    FEBS J; 2007 Oct; 274(19):4944-50. PubMed ID: 17894779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycogen storage disease with ventricular hypertrophy mimicking obstructive hypertrophic myocardiopathy.
    Guo LL; Fang LG; Zhu WL; Ding GF
    Chin Med J (Engl); 2012 Aug; 125(16):2954-6. PubMed ID: 22932100
    [No Abstract]   [Full Text] [Related]  

  • 31. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
    Lachmann RH
    Drugs Today (Barc); 2006 Jan; 42(1):29-38. PubMed ID: 16511609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
    Trapero A; Llebaria A
    Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ENZYMES IN MENTAL RETARDATION. II.
    ROSANOVA AR; NEIMEYER H; COMPALL T; MICHAELSON AS
    IMJ Ill Med J; 1964 Sep; 126():335-41. PubMed ID: 14199874
    [No Abstract]   [Full Text] [Related]  

  • 35. The role of antibodies in enzyme treatments and therapeutic strategies.
    Bigger BW; Saif M; Linthorst GE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prospects for the therapeutic use of liposomes in the medical practice].
    Synovets OA; Lapshin DE; Rudenko IuV
    Vrach Delo; 1991 Jun; (6):16-20. PubMed ID: 1891840
    [No Abstract]   [Full Text] [Related]  

  • 37. The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease.
    Hollak CE; Weinreb NJ
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):205-18. PubMed ID: 25987174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Congenital lysosomal diseases].
    Romanowska-Gõrecka B
    Pol Arch Med Wewn; 1972 Apr; 48(4):425-9. PubMed ID: 4556749
    [No Abstract]   [Full Text] [Related]  

  • 39. [How does the landscape change in lysosomal storage disease].
    Parini R
    Pediatr Med Chir; 2007; 29(5):275-8. PubMed ID: 18402399
    [No Abstract]   [Full Text] [Related]  

  • 40. [Case of type I glycogenosis. Considerations on its treatment with glucagon].
    Pessina S; Masarone M
    Minerva Pediatr; 1970 Sep; 22(37):1849-52. PubMed ID: 5273686
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.